Ex Vivo Organ Perfusion Market Size, Share, and Industry Analysis, By Offering (Product {Systems, and Disposable & Consumables} and Services), By Organ Type (Liver, Lung, Heart, Kidney, and Others), By End-user (Transplant Centers, Academic & Research Institutes, Organ Procurement Organizations (OPOs), and Others), and Regional Forecast till 2034

The ex vivo organ perfusion market size was valued at USD 560.2 million in 2025 and is expected to reach a market valuation of USD 625.2 million in 2026. Furthermore, the market is projected to reach a market valuation of USD 1,505.5 million by 2034, exhibiting a CAGR of 11.6% during the forecast period.

The market growth is attributed to the increasing incidence of organ failure globally and the increasing requirement for organ transplants. In such a scenario, the growing reliance on donation after circulatory death (DCD) and extended criteria donors (ECD) is a major driver of ex vivo organ perfusion adoption.

Ex Vivo Organ Perfusion Market Driver

Rising Global Transplant Volumes and Waitlist Expansion to Drive the Market Growth

Over the past few years, there have been an increasing cases of end-stage organ diseases due to aging populations, diabetes, cardiovascular disease, and chronic liver disease, which has increased the transplant waiting lists, driving the need for transplant infrastructure and organ utilization efficiency. In such a scenario, ex vivo perfusion plays a critical role in increasing organ acceptance rates and reducing discard rates, thereby augmenting market growth.

• For instance, according to data published by the United Network for Organ Sharing in January 2025, 48,149 organ transplants were performed in the U.S. in 2024.

Download Free sample to learn more about this report.

According to data published by the World Health Organization (WHO), 42,497 liver transplants were performed worldwide in 2024, a 4.0% increase from 2023.

Ex Vivo Organ Perfusion Market Restraint

High Capital Cost of Perfusion Systems to Hamper the Market Growth

Ex vivo organ perfusion systems require significant upfront investment, and disposable kits and perfusates add substantial per-procedure costs. These higher costs may challenge the adoption of perfusion systems among smaller transplant centers and emerging markets, where reimbursement is limited or inconsistent. This is expected to hamper market growth in the coming years.

Ex Vivo Organ Perfusion Market Opportunity

Expansion into Heart and Lung Normothermic Perfusion to Offer Significant Growth Opportunity

In recent years, heart and lung transplantation have rapidly adopted normothermic perfusion technologies, presenting significant opportunities for key players to expand related product offerings. Moreover, the higher waiting list for organ transplantation and continued expansion in thoracic transplantation volumes are expected to offer a significant opportunity for premium-priced systems.

• For instance, as of February 2026, NHS.uk stated that around 8,252 people are waiting for an organ transplant in the U.K.

Segmentation

Key Insights

The report covers the following key insights:

• Organ Transplantation Statistics, by Key Countries/Region, 2025
• Technological Advancements in Ex Vivo Organ Perfusion
• Key Industry Developments - (Partnerships, Mergers, and Acquisitions, etc.)

Analysis by Offering

By offering, the market is segmented into product and services. The product segment is sub-segmented into systems, and disposable & consumables.

The product segment is expected to hold the major share of the global market during the forecast period. The segment’s growth is driven by advances in ex vivo perfusion systems and global purchase rates, leading to higher penetration. Moreover, recurring consumable usage is also supporting the growth of the product segment.

Analysis by Organ Type

By organ type, the market is segmented into liver, lung, heart, kidney, and others.

The liver segment is expected to hold the major share of the global market during the forecast period. The segment’s growth is attributed to the higher global volume of liver transplants compared to other organs, which is driving demand for ex vivo organ perfusion systems.

• For instance, according to data from the American Liver Foundation, in 2024, the U.S. recorded 11,458 liver transplants. Among these, 10,854 were from deceased donors and 604 from living donors.

Analysis by End-user

Based on end-user, the market is divided into transplant centers, academic & research institutes, organ procurement organizations (OPOs), and others.

The transplant centers segment is expected to hold the largest share of the global market during the forecast period. Transplant centers account for the majority of system installations and consumable use, as they perform more implantation surgeries, conduct organ viability assessments, and control procurement decisions in many regions.

Regional Analysis

Request for Customization   to gain extensive market insights.

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for a 47.3% share of the global ex vivo organ perfusion market in 2025. The growth is driven by the highest transplant volumes, early FDA approvals for perfusion systems, and a well-structured organ procurement organization (OPO) network in the region.

• For instance, in January 2026, Bridge to Life Ltd. secured FDA De Novo clearance for its VitaSmart Hypothermic Oxygenated Perfusion (HOPE) System, the first U.S.-cleared device for hypothermic oxygenated perfusion of donor livers post-cold storage and pre-transplant.

Asia Pacific is expected to grow at the highest CAGR during the forecast period. The region’s growth is attributed to expanding transplant infrastructure, rising chronic disease burden, and increasing government focus on organ donation.

Key Players Covered

The global market for ex vivo organ perfusion is moderately consolidated, with key players competing primarily on technology differentiation, clinical validation, and installed base expansion.

The report includes the profiles of the following key players:

• TransMedics, Inc. (U.S.)
• XVIVO (Sweden)
• OrganOx, Inc. (U.K.)
• PARAGONIX (U.S.)
• Bridge to Life Ltd. (U.K.)
• Lung Bioengineering (U.S.)
• Organ Recovery Systems (U.S.)

Key Industry Developments

• October 2025: Bridge to Life Ltd. received FDA 510(k) clearance for its multi-sourced Belzer UW and MPS organ preservation solutions.
• October 2024: United Therapeutics Corporation and Lung Bioengineering announced the 500th lung transplant using their centralized ex vivo lung perfusion (EVLP) service.